Drug intelligence / Profile preview

CVXL-0069

Development stage: Preclinical
Lead developer: CleveXel Pharma
Modality: Small Molecules

Overview

CVXL-0069 is a small molecule dual modulator of the adenosine A1 and A2A receptors, currently being developed by CleveXel Pharma. The program is in the IND-enabling stage, preparing for clinical entry. Adenosine receptors are G protein-coupled receptors (GPCRs) that mediate the effects of extracellular adenosine, influencing diverse biological systems including the central nervous system, cardiovascular system, and immune response. While CleveXel has not specified the primary therapeutic indication for CVXL-0069, compounds targeting these receptors are frequently investigated for potential applications in neurodegenerative diseases, pain management, or inflammatory disorders.

Targets

ADORA2A (Adenosine A₂A Receptor)ADORA1 (Adenosine receptor A1 subtype)

Beyond the preview

Go deeper on CVXL-0069.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVXL-0069.

Explore the full profile